Recurrent glioblastoma patients treated with dasatinib alone or in combination with CCNU (cyclonexyl-chloroethyl-nitrosourea) did not demonstrate favourable outcomes, with a median PFS of less than two months.191,192 The combination of dasatinib and bevacizumab resulted in higher PFS time of 3.2 months in recurrent glioblastoma patients, although these outcomes are not superior to bevacizumab treatment alone.193 Pexidartinib is an inhibitor of c-KIT, FLT3, and colony-stimulating factor 1 (CSF-1), a receptor that belongs to the PDGFR family. Here, FLT3 is linked to glioblastoma.